文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛消化、代谢与肾脏急症

重症军团菌病

Severe Legionnaires' disease.
PubMed 文献 · Ann Intensive Care · 2024-04-02
一句话结论军团菌病是需ICU入住的重症社区获得性肺炎常见病因之一,ICU患者、免疫抑制患者及医院获得性感染者病死率可达40%。

该综述讨论重症军团菌病(LD)的近期进展,涵盖诊断、发病机制与管理。LD约占全部社区获得性肺炎(CAP)的5%,却位列需ICU入住的CAP三大常见病因;约三分之一病例需ICU入住,病死率4%–40%,ICU患者、免疫抑制患者或医院获得性LD患者病死率可达40%(即使接受恰当抗菌治疗)。诊断因尿抗原检测(UAT)的广泛使用和可检出所有Lp血清群的分子方法而改善;治疗以大环内酯类、喹诺酮类或两者联合为基础,重症病例延长疗程。

要点

  • LD约占全部CAP的5%,但位列需ICU入住的CAP三大常见病因之一,约三分之一病例需ICU入住。
  • ICU患者、免疫抑制患者或医院获得性LD患者病死率可达40%,即使接受恰当抗菌治疗。
  • 尿抗原检测(UAT)广泛使用及可检出所有Lp血清群的分子方法使LD诊断得到改善。
  • 治疗以大环内酯类、喹诺酮类或两者联合为基础,重症病例延长疗程。
  • 重症病例可见高肺部军团菌DNA载量、免疫应答受损及肺微生物组改变;尚无军团菌特异性毒力因子与严重程度相关。

适用人群与场景

  • 社区获得性肺炎(CAP)患者,尤其需ICU入住者;约三分之一LD病例需ICU入住。
  • 免疫抑制患者及医院获得性LD患者为病死率增高的人群。

处置流程与药物剂量

  • 治疗以大环内酯类、喹诺酮类或两者联合为基础,重症病例延长疗程。

红旗征与不能漏的情况

  • 严重肺损伤需呼吸和/或血流动力学支持,提示重症LD。
  • 肺外症状及非特异性实验室检查结果可见于LD。

研究设计与关键结果

  • 综述指出:近年来全球LD总体发病率上升,与危险因素患者(尤其免疫抑制)增多及诊断方法改进有关。
  • LD约占全部CAP的5%,却位列需ICU入住的CAP三大常见病因之一。
  • ICU患者、免疫抑制患者或医院获得性LD患者病死率可达40%,即使接受恰当抗菌治疗。
  • 发病机制方面,尚无军团菌特异性毒力因子与严重程度相关;近期报告发现最严重病例存在高肺部军团菌DNA载量、免疫应答受损及肺微生物组改变。
  • 诊断方法因UAT广泛使用及可检出所有Lp血清群的分子方法发展而改善。

证据类型、等级与局限

  • 证据类型:综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,鉴于LD发病率上升,关于严重程度特异性生物标志物的研究可能具有重要价值。
  • 作者认为,目前需要进一步评估比较不同治疗方案和/或评估宿主导向治疗。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Legionnaires' disease (LD) is a common but under-diagnosed cause of community-acquired pneumonia (CAP), although rapid detection of urine antigen testing (UAT) and advances in molecular testing have improved the diagnosis. LD entails intensive care unit (ICU) admission in almost one-third of cases, and the mortality rate ranges from 4% to 40%. This review aims to discuss recent advances in the study of this condition and to provide an update on the diagnosis, pathogenesis and management of severe LD.

RESULTS: The overall incidence of LD has increased worldwide in recent years due to the higher number of patients with risk factors, especially immunosuppression, and to improvements in diagnostic methods. Although LD is responsible for only around 5% of all-cause CAP, it is one of the three most common causes of CAP requiring ICU admission. Mortality in ICU patients, immunocompromised patients or patients with a nosocomial source of LD can reach 40% despite appropriate antimicrobial therapy. Regarding pathogenesis, no Legionella-specific virulence factors have been associated with severity; however, recent reports have found high pulmonary Legionella DNA loads, and impairments in immune response and lung microbiome in the most severe cases. The clinical picture includes severe lung injury requiring respiratory and/or hemodynamic support, extrapulmonary symptoms and non-specific laboratory findings. LD diagnostic methods have improved due to the broad use of UAT and the development of molecular methods allowing the detection of all Lp serogroups. Therapy is currently based on macrolides, quinolones, or a combination of the two, with prolonged treatment in severe cases.

CONCLUSIONS: Numerous factors influence the mortality rate of LD, such as ICU admission, the underlying immune status, and the nosocomial source of the infection. The host immune response (hyperinflammation and/or immunoparalysis) may also be associated with increased severity. Given that the incidence of LD is rising, studies on specific biomarkers of severity may be of great interest. Further assessments comparing different regimens and/or evaluating host-directed therapies are nowadays needed.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Rello J, Allam C, Ruiz-Spinelli A, et al. Severe Legionnaires' disease. Ann Intensive Care. 2024. PMID: 38565811. doi:10.1186/s13613-024-01252-y

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。